Fulgent Genetics Hits New 52-Week Low at $14.01 Amid Declining Performance

Fulgent Genetics, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 14.01 as of March 2, 2026. This decline marks a significant downturn for the company, which has seen its stock price drop by 30.29% over the past year, contrasting sharply with the S&P 500's performance of 17.36% during the same period. The company's market capitalization stands at USD 717 million, and it currently operates at a loss, reflected in its negative price-to-earnings ratio. Fulgent Genetics has not offered dividends, maintaining a yield of 0.00%. Its debt-to-equity ratio is reported at -0.33, indicating a unique financial structure, while the return on equity is at -3.04%. The price-to-book ratio is relatively low at 0.64, suggesting that the stock may be undervalued compared to its book value. Despite the challenges, Fulgent Genetics has seen a notable increase in interest, with operating cash flow recorded at USD 1.53 million. Institutional holdings remain robust at 63.82%, reflecting confidence from larger investors in the company's fundamentals. However, the stock has consistently underperformed against the S&P 500 over the last three years, raising questions about its market position.